Evidence map›Paper›PMID 26083328›Full record

ArticleRedox report : communications in free radical research2016

The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial.

Lei Zhang, Jeff Coombes, Elaine M Pascoe, Sunil V Badve, Kim Dalziel, Alan Cass, Philip Clarke, Paolo Ferrari, Stephen P McDonald, Alicia T Morrish and 9 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox report : communications in free radical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Antioxidants for adults with chronic kidney disease.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Lei Zhanga Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Jeff Coombesc School of Human Movement Studies , University of Queensland , Brisbane , Australia.
Elaine M Pascoea Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Sunil V Badvea Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Kim Dalziele Center for Health Policy, Programs & Economics , University of Melbourne , Australia.
Alan Cassa Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Philip Clarkee Center for Health Policy, Programs & Economics , University of Melbourne , Australia.
Paolo Ferraria Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Stephen P McDonalda Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Alicia T Morrisha Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Eugenie Pedagogosa Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Vlado Perkovica Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Donna Reidlingera Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Anish Scariaa Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Rowan Walkera Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Liza A Vergaraa Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
Carmel M Hawleya Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
David W Johnsona Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
On Behalf Of The Hero Study Collaborative Group
The University of Queensland · AUKidney Health Australia · AUThe University of Melbourne · AUPrincess Alexandra Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients.

methodsThis sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities.

resultsPentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD -6.06 U/l, P = 0.09), or protein carbonyls (MD -0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04).

conclusionsPentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.

Indexed as

AnaemiaChronic kidney diseaseErythropoiesis-stimulating agentOxidative stressPentoxifylline

Identifiers

PMID26083328
PMCPMC6837737
OpenAlexW1591447874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.